生物股份非洲猪瘟亚单位疫苗首轮攻毒评价实验成功 加速向高端领域迈进

Group 1 - The core point of the article is that Jin Yu Biotechnology Co., Ltd. has successfully completed the first round of clinical trials for its African swine fever subunit vaccine, achieving a protection rate that meets evaluation standards [2] - Since the outbreak of African swine fever in China in 2018, the domestic pig farming industry has suffered economic losses exceeding 1 trillion yuan [2] - The vaccine development has been a collaborative effort involving multiple institutions, with a total investment of nearly 600 million yuan over seven years, focusing on four major technological routes: gene-deleted live vaccines, vector vaccines, subunit vaccines, and mRNA vaccines [2] Group 2 - The African swine fever subunit vaccine received clinical trial approval from the Ministry of Agriculture and Rural Affairs in July 2025, becoming the first subunit vaccine in China to enter clinical stages [2] - The first round of challenge experiments for the vaccine was successfully completed in January 2026, utilizing a genetic engineering subunit technology that expresses only eight conserved antigen proteins, eliminating the risk of virulence reversion [2] - The company has established a high-throughput molecular screening platform, completing AI screening and synthesis of over 100 African swine fever target proteins, providing substantial data for future responses to new strains [3]